ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Protective effects of diacerein against quinolinic acid-induced Huntington's disease-like symptoms in adult zebrafish by targeting GSK-3β signalling.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Targeting oxidative stress, senescence, and neurodegeneration: anti-aging perspectives of Urtica dioica and Centella asiatica.Inflammopharmacology · 2026Review
- The kynurenine pathway storm in epilepsy: mechanisms and therapeutic implications.Acta epileptologica · 2026Review
- Neuroprotective effects of traditional Chinese medicine using zebrafish models - a review.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Huntington's disease is a brain-related hereditary condition characterized by a gradual loss of mental, physical, and emotional function. Quinolinic acid is a toxic substance that is formed because of the breakdown of tryptophan, a compound involved in the metabolism of the amino acid. Diacerein is an anthraquinone which shows anti-inflammatory effects. The binding capacity of diacerein on GSK-3β is screened via Auto Dock. The purpose of the study is to check neuroprotective and anti-inflammatory properties of diacerein on QA-induced HD in adult zebra fish. In this study, 14 fish in each group were used, QA was administered by i.c.v. route as a toxin on the day 0, and diacerein (25 and 50 mg/kg) as treatment and tetrabenazine as standard were used for 14 days. We have performed three neurobehavioral parameters such as open-field (for locomotion), T-maze (for memory), and novel diving test (for anxiety), followed by biochemical parameters such as total protein estimation, LPO, GSH, nitrite, AChEs, and catalase, neurotransmitters (GABA and glutamate) along with inflammatory markers (IL-1β, TNF-α, and IL-17), and histopathological evaluation at the end. Diacerein enhances motor function, modulates neurotransmitter levels, diminishes oxidative stress markers, controls the generation of inflammatory cytokines, and inhibits GSK-3β activity. Furthermore, diacerein improves the neurotoxicity and neurobehavioral impairments in adult zebra fish with Huntington's disease-like symptoms caused by quinolinic acid.
Indexed as
Identifiers
40042555What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.